Phathom Pharmaceuticals, Inc. Weighted Average Shares Growth

Weighted Average Shares Growth of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Weighted Average Shares Growth growth rates and interactive chart.


Highlights and Quick Summary

  • Weighted Average Shares Growth for the quarter ending September 29, 2021 was 11.79% (a 6.89% increase compared to previous quarter)
  • Year-over-year quarterly Weighted Average Shares Growth decreased by -94.09%
  • Annual Weighted Average Shares Growth for 2020 was 34.37% (a 4091.46% increase from previous year)
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Weighted Average Shares Growth of Phathom Pharmaceuticals, Inc.

Most recent Weighted Average Shares Growthof PHAT including historical data for past 10 years.

Interactive Chart of Weighted Average Shares Growth of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Weighted Average Shares Growth for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 11.79% 11.03% 11.79%
2020 199.64% 355.45% 392.86% 393.02% 34.37%
2019 68.15% 0.82%

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.